NuVasive (NSDQ:NUVA) said today it launched three new products as part of its biologics portfolio, including its Traditional Bone Allograft, Amniotic Membrate DS and Propel DBM.
The San Diego-based company’s Traditional Bone Allograft includes cancellous chips, demineralized cancellous chips, cortical cancellous chips and cancellous crushed, which the company claims the has osteoconductive properties intended to provide a scaffold for bone growth.
The newly launched Amniotic Membrane DS is a dual-sided layer of human amniotic membrane intended to act as a biologic barrier to prevent adhesions and reduce scar tissue formation near adjacent muscle, nerve and fascia layer tissues.
The Propel DBM, which was originally launched last year, now includes gel, gel plus and putty plus form factors. The gel is packaged in a syringe, while the putty plus and gel plus contain cancellous chips which the company claims has additional osteoconductive properties which help promote bone growth.
“The addition of these three new product lines strengthens our comprehensive spine portfolio and further positions NuVasive as a full-service provider of biologics. NuVasive is committed to investing in innovative offerings to meet the clinical and economic needs of our patients, surgeons and hospital partners,” strategy, tech & corp dev exec VP Matt Link said in a press release.
Last month, NuVasive said that it inked a strategic partnership deal with Siemens (NYSE:SI) Healthineers looking to develop and advance technology designed for minimally invasive spinal surgery.
